207 related articles for article (PubMed ID: 24038885)
1. How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity?
Cohen IJ; Wolff JE
Pediatr Blood Cancer; 2014 Jan; 61(1):7-10. PubMed ID: 24038885
[TBL] [Abstract][Full Text] [Related]
2. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.
Skärby TV; Anderson H; Heldrup J; Kanerva JA; Seidel H; Schmiegelow K;
Leukemia; 2006 Nov; 20(11):1955-62. PubMed ID: 16990760
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
4. [l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate].
Etienne MC; Thyss A; Bertrand Y; Rubie H; Milano G
Bull Cancer; 1993 Apr; 80(4):357-63. PubMed ID: 8173189
[TBL] [Abstract][Full Text] [Related]
5. Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue.
Cohen IJ
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1057-1065. PubMed ID: 28455583
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
[TBL] [Abstract][Full Text] [Related]
7. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?
Sterba J; Valík D; Bajciová V; Kadlecová V; Gregorová V; Mendelová D
Neoplasma; 2005; 52(6):456-63. PubMed ID: 16284689
[TBL] [Abstract][Full Text] [Related]
8. Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia.
Oosterom N; de Jonge R; Smith DEC; Pieters R; Tissing WJE; Fiocco M; van Zelst BD; van den Heuvel-Eibrink MM; Heil SG
PLoS One; 2019; 14(9):e0221591. PubMed ID: 31527879
[TBL] [Abstract][Full Text] [Related]
9. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
[TBL] [Abstract][Full Text] [Related]
10. Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX).
Cohen IJ
Med Hypotheses; 2013 Nov; 81(5):942-7. PubMed ID: 24035689
[TBL] [Abstract][Full Text] [Related]
11. How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia.
Borsi JD; Wesenberg F; Stokland T; Moe PJ
Eur J Cancer; 1991; 27(8):1006-9. PubMed ID: 1832883
[TBL] [Abstract][Full Text] [Related]
12. A rare complication of intrathecal methotrexate in a child with acute lymphoblastic leukemia.
Tufekci O; Yilmaz S; Karapinar TH; Gozmen S; Cakmakci H; Hiz S; Irken G; Oren H
Pediatr Hematol Oncol; 2011 Sep; 28(6):517-22. PubMed ID: 21699468
[TBL] [Abstract][Full Text] [Related]
13. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system.
Cohen IJ
J Pediatr Hematol Oncol; 2004 Mar; 26(3):156-63. PubMed ID: 15125607
[TBL] [Abstract][Full Text] [Related]
14. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
Vaishnavi K; Bansal D; Trehan A; Jain R; Attri SV
Pediatr Blood Cancer; 2018 Dec; 65(12):e27241. PubMed ID: 29768710
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia.
Oosterom N; Fiocco M; Kloos RQH; van der Sluis IM; Pieters R; van Zelst BD; Smith DEC; van den Heuvel-Eibrink MM; de Jonge R; Heil SG
BMC Cancer; 2020 Sep; 20(1):940. PubMed ID: 32998716
[TBL] [Abstract][Full Text] [Related]
16. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
[TBL] [Abstract][Full Text] [Related]
17. Reduced dose folinic acid rescue after rapid high-dose methotrexate clearance is not associated with increased toxicity in a pediatric cohort.
Niinimäki R; Aarnivala H; Banerjee J; Pokka T; Vepsäläinen K; Harila-Saari A
Support Care Cancer; 2022 Jan; 30(1):127-133. PubMed ID: 34235555
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
19. [Munchhausen syndrome by proxy revealed by falsely toxic methotrexate levels].
Charfi R; Trabelsi S; Salouage I; Gaïes E; Jebabli N; Lakhal M; Klouz A
Ann Biol Clin (Paris); 2012; 70(2):221-5. PubMed ID: 22484536
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
